Drug intelligence / Profile preview

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)]

Development stage: Unknown
Lead developer: Avanti Polar Lipids
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous, Topical, Ophthalmic

Overview

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)] (DSPE-mPEG) is a PEGylated phospholipid widely utilized as a functional excipient in the development of advanced drug delivery systems, such as liposomes, micelles, and nanostructured lipid carriers. It consists of a hydrophobic distearoylphosphatidylethanolamine (DSPE) anchor and a hydrophilic methoxy-polyethylene glycol (mPEG) headgroup. When incorporated into lipid bilayers, the PEG chains extend outward to create a hydrophilic steric barrier. This barrier effectively inhibits opsonization and subsequent recognition by the mononuclear phagocyte system (MPS), thereby significantly extending the systemic circulation half-life of encapsulated therapeutic agents (the "stealth" effect). DSPE-mPEG is a critical component of several FDA-approved liposomal drugs, including liposomal doxorubicin (Doxil) and liposomal irinotecan (Onivyde), where it facilitates improved tumor accumulation via the enhanced permeability and retention (EPR) effect.

Other names: Distearoylphosphatidylethanolamine-methylpolyethylene glycolPEGylated DSPEN-(Carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamineMPEG-DSPE

Beyond the preview

Go deeper on 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)].

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)].

Explore the full profile